Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Aerospace systems provider Astronics Corporation launches its new automated circuit card testing system, designed to accelerate troubleshooting and maintenance for critical aviation and defense electronics, as analysts raise price targets on sustained sector demand.
CareDx CEO John Hanna sold over 19,000 shares under a pre-arranged trading plan, a move that comes as the transplant diagnostics firm posts strong revenue growth but continues to navigate a challenging stock market environment.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
A multi-agency search operation is underway for 19-year-old Matthew Packard-Asai, who was swept into the ocean while fishing on a rocky Kauai shoreline last week. One companion was rescued.
Amid rising electricity prices and shifting federal incentives, solar platform GigaWatt is turning to crowd-investing to accelerate its push into integrated, user-friendly DIY solar kits, betting on AI and streamlined hardware to capture a growing market.
With pharmaceutical companies increasingly deploying AI in direct-to-consumer platforms, the regulatory landscape remains fragmented. In the absence of comprehensive federal action, states are stepping in with disparate laws to address privacy and safety concerns, creating a complex compliance challenge for the industry.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
As financial pressures and a search for engagement redefine retirement, a new wave of seniors is turning to flexible, low-barrier side gigs. From online tutoring to pet care, these roles leverage lifelong skills without requiring prior formal experience.
While the FTSE 100 grapples with global headwinds, a segment of smaller UK-listed companies presents distinct opportunities. We examine three firms, each with a market capitalisation over £90 million, that combine financial resilience with specific growth catalysts.
Amid a patchy eurozone recovery, investors are scanning the market's fringes for potential. We spotlight three small-cap stocks from Norway and Sweden, each navigating unique challenges while showing flashes of promise for the discerning, risk-tolerant investor.
Danaher Corporation announces a strategic investment in Automata, aiming to integrate AI-ready automation systems with its extensive portfolio of instruments and reagents. The move signals a push to deliver comprehensive, data-driven lab solutions as the life sciences sector increasingly prioritizes efficiency and scalability.
A massive release of Jeffrey Epstein-related documents by the Justice Department includes emails showing Commerce Secretary Howard Lutnick planned a 2012 lunch on the financier's private island, despite previous assertions he had severed ties. The files also contain communications involving Donald Trump and Elon Musk, fueling ongoing political and legal scrutiny.
While large-cap stocks offer stability, their massive scale often limits growth. We analyze three market leaders, identifying one with compelling potential and two where the current story may be fully priced in.
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
Goldman Sachs and Evercore ISI analysts have raised price targets for GE HealthCare Technologies (GEHC), citing a projected market recovery and strong capital expenditure trends by 2026. The medical devices firm is highlighted as a top hedge fund pick.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
Facing ongoing labor disputes, Starbucks unveils a massive investment in new espresso machines, AI-assisted POS systems, and a store rating program aimed at streamlining operations and improving the partner experience.
Despite significant institutional purchases and regulatory progress, Bitcoin continues to drift lower, leading analysts and investors to question what price level will finally stem the tide.
